Wen-Jen Hwu

Wen-Jen Hwu

Auto-generated profile, based on publicly available information

Wen-Jen Hwu

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2018 in Science
Verified
Journal Article
Closed access
PDF file
VGVancheswaran Gopalakrishnan
Vancheswaran Gopalakrishnan
CSC. N. Spencer
C. N. Spencer
LNLuigi Nezi
Luigi Nezi
Alexandre ReubenAlexandre Reuben
Alexandre Reuben
MAMiles C. Andrews
Miles C. Andrews
JWJennifer A. Wargo
Jennifer A. Wargo
Good bacteria help fight cancer: Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32

1 March 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
WRWhijae Roh
Whijae Roh
PCPei-Ling Chen
Pei-Ling Chen
Alexandre ReubenAlexandre Reuben
Alexandre Reuben
CSChristine N. Spencer
Christine N. Spencer
PPPeter A. Prieto
Peter A. Prieto
PFP. Andrew Futreal
P. Andrew Futreal
Profiling of melanoma patients treated with checkpoint blockade reveals TCR clonality and copy number loss as correlates of therapeutic response.

24 December 2020 in European Journal of Cancer
Verified
Journal Article
Open access
Caroline RobertCaroline Robert
Caroline Robert
WHWen-Jen Hwu
Wen-Jen Hwu
OHOmid Hamid
Omid Hamid
ARAntoni Ribas
Antoni Ribas
JWJeffrey S. Weber
Jeffrey S. Weber
AJAnthony Joshua
Anthony Joshua
Long-term safety of pembrolizumab in melanoma was analyzed in KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006. Analysis involved patients who received ≥1 pembrolizumab dose. Lead-time bias was addressed via landmark analyses in patients who were progression-free before day 147. Adverse events (AEs) were analyzed for 1567 patients (median follow-up, 42.4 months). Most AEs were mild/moderate; grade 3/4 treatment-related AEs occurred in 17.7% of patients. Two pembrolizumab-related deaths occurred. Any-grade immune-mediated AEs (imAEs) occurred in 23.0%, most commonly hypothyroidism (9.1%), pneumonitis (3.3%), and hyperthyroidism (3.0%); grade 3/4 imAEs occurred in 6.9% of patients. Most imAEs occurred within 16 weeks of treatment. In landmark analysis, patients who did (n = 79) versus did not (n = 384) develop imAEs had similar objective response rates (ORRs) (64.6% versus 63.0%); median time to response (TTR), 5.6 months for both; median duration of response (DOR), 20.0 versus 25.3 months; median progression-free survival (PFS), 17.0 versus 17.7 months; median overall survival (OS), not reached (NR) versus 43 months (p = 0.1104). Patients who did (n = 17) versus did not (n = 62) receive systemic corticosteroids had similar ORRs (70.6% vs. 62.9%) and median TTR (6.4 vs. 5.6 months) but numerically shorter median PFS (9.9 vs. 17.0 months); median DOR, 14.2 months versus NR; median OS, NR for both. These results enhance the knowledge base for pembrolizumab in advanced melanoma, with no new toxicity signals after lengthy follow-up of a large population. In landmark analyses, pembrolizumab efficacy was similar regardless of imAEs or systemic corticosteroid use. NCT01295827, NCT01704287, NCT01866319.

16 December 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Dinesh PradhanDinesh Pradhan
Dinesh Pradhan
George JourGeorge Jour
George Jour
DMDenái Milton
Denái Milton
VVVarshini Vasudevaraja
Varshini Vasudevaraja
MTMichael T. Tetzlaff
Michael T. Tetzlaff
Phyu P AungPhyu P Aung
Phyu P Aung
Acral melanoma (AM) is a rare, aggressive type of cutaneous melanoma (CM) with a distinct genetic profile. We aimed to identify a methylome signature distinguishing primary acral lentiginous melanoma (PALM) from primary non-lentiginous AM (NALM), metastatic ALM (MALM), primary non-acral CM (PCM), and acral nevus (AN). A total of 22 PALM, nine NALM, 10 MALM, nine PCM, and three AN were subjected to genome-wide methylation analysis using the Illumina Infinium Methylation EPIC array interrogating 866,562 CpG sites. A prominent finding was that the methylation profiles of PALM and NALM were distinct. Four of the genes most differentially methylated between PALM and NALM or MALM were HHEX, DIPK2A, NELFB, and TEF. However, when primary AMs (PALM + NALM) were compared with MALM, IFITM1 and SIK3 were the most differentially methylated, highlighting their pivotal role in the metastatic potential of AMs. Patients with NALM had significantly worse disease-specific survival (DSS) than patients with PALM. Aberrant methylation was significantly associated with aggressive clinicopathologic parameters and worse DSS. Our study emphasizes the importance of distinguishing the two epigenetically distinct subtypes of AM. We also identified novel epigenetic prognostic biomarkers that may serve to risk-stratify patients with AM and may be leveraged for the development of targeted therapies.

1 April 2011 in Melanoma Research
Verified
Journal Article
Closed access
GAGladys C. Alvarado
Gladys C. Alvarado
NPNicholas E. Papadopoulos
Nicholas E. Papadopoulos
WHWen-Jen Hwu
Wen-Jen Hwu
ABAgop Y. Bedikian
Agop Y. Bedikian
JHJade Homsi
Jade Homsi
KKKevin B. Kim
Kevin B. Kim
Although pelvic computed tomography (CT) scans are frequently performed as a part of routine surveillance, the evidence for or against the routine use of these scans in patients with primary melanoma in the head and neck is weak. We conducted a retrospective study to evaluate the value of pelvic CT scans as routine surveillance in patients with primary melanoma in the head and neck. We identified 146 patients with either primary or mucosal primary melanoma who had adequate follow-up evaluation for at least 5 years at our institution. Among them, 33 patients (23%) had stage III melanoma, and four (3%) had stage IV melanoma at the time of diagnosis. At a median follow-up duration of 49 months, 110 patients (75%) had developed recurrences, and the median time to the first recurrence was 13 months. A total of 82 (56%) patients had eventually developed distant metastases, but only 10 (7%) had developed metastases in the pelvis, and none had developed pelvic metastases as the first and the only site of recurrence. If the true rate of finding the pelvic metastasis as the first and the only recurrence was at least 3%, the probability of seeing 0 events of the 146 patients was 1.17%. This study, which is the largest series to evaluate the value of pelvic CT scans in this patient population to date, suggests that the routine use of a pelvic CT scan as a surveillance method does not have any impact on the management in patients with primary melanoma in the head and neck.

1 September 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
IGI.C. Glitza
I.C. Glitza
MRM.L. Rohlfs
M.L. Rohlfs
RBR. Bassett
R. Bassett
IJI. John
I. John
JRJ. Richard
J. Richard
MDM.A. Davies
M.A. Davies